A Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

• Status: Not yet recruiting
• Trial end date: 2026-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

To evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of radiographic progression-free survival (rPFS) in mCRPC subjects unselected for deoxyribonucleic acid (DNA) damage repair deficiencies (DRD) status (Cohort 1) to evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of rPFS in mCRPC subjects harboring DRD (Cohort 2).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.
• Treatments: Abiraterone Acetate; Prednisone

Criteria

Inclusion Criteria

1. Able and willing to provide a written informed consent

2. A score of 0 to 1 for ECOG performance status

3. Age of ≥ 18 years old

4. Prostate adenocarcinoma confirmed

5. Disease progression of metastatic prostate cancer while the subject was on androgen deprivation therapy.

6. The functional level of the organs must meet the requirements

7. Blood and tumor tissue samples are provided during screening to determine the DRD status

Exclusion Criteria

1. Prior treatment with any PARP inhibitor

2. Have received any systemic anti-tumor treatment during the mCRPC stage or non-metastatic CRPC stage

3. Have used any CYP3A4 inducers or inhibitors within 14 days prior to the first dose

4. Plan to receive any other anti-tumor treatment

5. Presence of radiologically confirmed tumor lesions in the brain

6. Contraindications to the use of Prednisone

7. History of uncontrolled pituitary or adrenal dysfunction

8. Uncontrolled hypertension

9. Presence of active heart diseases

10. Human immunodeficiency virus-positive

11. Presence of dysphagia, chronic diarrhea, intestinal obstruction, or other factors affecting drug intake and absorption

12. Active HBV or HCV infection

13. Presence of concomitant diseases